Source Count: 13 | Weighted Score: 29 | Source Confidence: [3/5] | Primary Tier: 1–2 | Last Updated: March 9, 2026
Keywords: pharmacogenomics, CYP2D6, CYP2C_5_04, drug metabolism, personalized medicine, warfarin, codeine, adverse drug reaction, genetic polymorphism, cytochrome P450, population variation, poor metabolizer, ultrarapid metabolizer, DPYD, HLA-B*57:01
Category Tags: genetics, medicine, health, evolution, population genetics
Cross-References: L_5_02 — Genetic Diseases Founder Populations · L_3_09 — HLA Diversity Immune Evolution · X_1_01 — Medicine Healing Overview · L_2_02 — Population Genetics Hardy-Weinberg

QUICK SUMMARY

Pharmacogenomics — the study of how genetic variation influences individual responses to drugs — bridges genetics, pharmacology, and clinical medicine. Humans carry extensive polymorphism in genes encoding drug-metabolizing enzymes, drug transporters, and drug targets, leading to wide variation in drug efficacy, dosing requirements, and adverse reaction risk. The cytochrome P450 (CYP) enzyme superfamily is central: CYP2D6 (the most polymorphic CYP gene, with >100 known alleles) metabolizes ~25% of all prescribed drugs (codeine, tamoxifen, antidepressants, antipsychotics, beta-blockers); individuals are classified as poor metabolizers (PMs, ~5–10% of Europeans, ~1–2% of East Asians), intermediate metabolizers, extensive (normal) metabolizers, or ultrarapid metabolizers (UMs, ~1–10% depending on population, up to ~29% in East Africa and the Middle East). These categories have life-or-death consequences: PM individuals cannot convert codeine to morphine (no pain relief), while UMs convert codeine so rapidly they risk fatal morphine toxicity — leading to FDA black-box warnings against codeine use in children after several pediatric deaths in UM children. CYP2C19 similarly influences clopidogrel (antiplatelet drug) activation — PMs have increased cardiovascular event risk. Warfarin dosing depends on polymorphisms in CYP2C9 and VKORC1 (vitamin K epoxide reductase), which together explain ~30–40% of warfarin dose variability; allele frequencies differ dramatically between populations (VKORC1 variants requiring lower warfarin doses are at ~90% frequency in East Asians vs. ~35% in Europeans). Pharmacogenomic variation across populations reflects evolutionary history — natural selection, genetic drift, and differential exposure to toxins and dietary compounds in ancestral environments shaped the enzyme repertoire of modern populations.

1. VERIFIED CLAIMS (Tier 1 — Peer-Reviewed / Scholarly Consensus)

1.1 CYP2D6 and Drug Metabolism

• CYP2D6 is the most polymorphic human drug-metabolizing enzyme; it metabolizes ~25% of all prescribed drugs including codeine, tramadol, tamoxifen, fluoxetine, risperidone, metoprolol, dextromethorphan, and many opioids
• The gene has >100 alleles with variable activity: CYP2D61 (normal function), CYP2D64 (non-functional, most common PM allele in Europeans, ~20–25% frequency), CYP2D610 (reduced function, most common in East Asians), and gene duplications/multiplications (CYP2D61xN or CYP2D62xN, causing ultrarapid metabolism)
• PM frequency: ~5–10% of Europeans, ~1–2% of East Asians, ~1–3% of sub-Saharan Africans; UM frequency: ~1–2% of Northern Europeans, ~7–10% of Southern Europeans, ~16–29% in parts of East Africa and the Middle East
• Clinical significance: codeine is a prodrug converted to morphine by CYP2D6 — PMs get no pain relief (codeine is ineffective), while UMs produce toxic morphine levels (several pediatric deaths reported in UM children receiving codeine → FDA 2013 warning, 2017 contraindication for children)

1.2 Warfarin Pharmacogenomics

• Warfarin (coumarin anticoagulant) has a narrow therapeutic index; dosing is influenced by polymorphisms in CYP2C9 (metabolizes S-warfarin) and VKORC1 (warfarin's target)
• CYP2C9 2 and 3 alleles (reduced function) are common in Europeans (~12% and ~8%) but rare in East Asians (<1%) and Africans (~1–3%); carriers require lower warfarin doses
• VKORC1 −1639G>A: the A allele (associated with lower warfarin dose requirement) is at ~90% frequency in East Asians, ~35–45% in Europeans, and ~10–14% in Africans — explaining the well-known clinical observation that East Asian patients require ~30–40% lower warfarin doses than European patients
• FDA-approved warfarin labeling includes pharmacogenomic dosing recommendations based on CYP2C9 and VKORC1 genotype

1.3 HLA-Mediated Drug Hypersensitivity

• Certain HLA alleles predict severe adverse drug reactions:
• HLA-B57:01 → abacavir hypersensitivity syndrome (an HIV drug); pre-prescription HLA-B57:01 testing is standard of care and has virtually eliminated this reaction
• HLA-B*15:02 → carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), most common in Southeast Asian populations (frequency ~8% in Han Chinese); FDA recommends screening before prescribing carbamazepine to patients of Southeast Asian ancestry
• HLA-B*58:01 → allopurinol hypersensitivity, particularly in Southeast Asian and African American populations

2. CREDIBLE CLAIMS (Tier 2 — Academic / Debated but Supported)

2.1 Evolutionary Origins of Pharmacogenomic Variation

• CYP enzyme polymorphism likely reflects ancestral dietary and environmental exposures: populations with long histories of consuming specific plant alkaloids, mycotoxins, or cooked foods may have been selected for different metabolic capacities
• The high UM frequency for CYP2D6 in East Africa has been hypothesized to reflect selection for rapid metabolism of environmental xenobiotics or dietary compounds, though the specific selective agent is unknown
• CYP2A6 (nicotine metabolism) shows extensive population variation: high-activity alleles are more common in populations with long tobacco use history, though this correlation may be coincidental

2.2 Clinical Implementation Challenges

• Despite strong evidence for several gene-drug pairs, clinical implementation of pharmacogenomics has been slower than anticipated; barriers include: cost of genetic testing, limited physician training in pharmacogenomics, complex multi-gene interactions, incomplete clinical evidence for many drug-gene pairs, and regulatory/insurance coverage gaps
• The Clinical Pharmacogenetics Implementation Consortium (CPIC) has published evidence-based guidelines for >25 gene-drug pairs with actionable prescribing recommendations

3. SPECULATIVE CLAIMS (Tier 3 — Possible but Unverified)

3.1 Universal Pre-Emptive Pharmacogenomic Testing

• Some advocates propose pre-emptive panel testing (genotyping a panel of pharmacogenes in all patients before any drug is prescribed, storing results in electronic health records for future prescribing decisions); pilot programs (e.g., at St. Jude Children's Research Hospital, Vanderbilt, and the Netherlands) show feasibility, but cost-effectiveness and clinical impact at the population level remain under evaluation

4. DUBIOUS CLAIMS (Tier 4 — No Credible Source / Contradicted by Evidence)

4.1 "Race-Based" Drug Prescribing as Pharmacogenomics

• DEBUNKED The controversial race-specific heart failure drug BiDil (isosorbide dinitrate/hydralazine, FDA-approved 2005 specifically for self-identified African Americans) was marketed as pharmacogenomics but was actually based on a subgroup analysis of a clinical trial, not on any identified genetic variant — confounding racial identity with genetic variation

Counter-Arguments

• Pharmacogenomics uses specific genotypes (not race) to guide therapy; while allele frequencies differ between populations, individual genotyping is always more informative and accurate than racial categorization for drug prescribing

IMAGES

No images assigned yet.

BIBLIOGRAPHY

1. Ingelman-Sundberg, M | 2004 | "Pharmacogenetics of Cytochrome P450 and Its Applications in Drug Therapy: The Past, Present and Future" | Trends in Pharmacological Sciences | ∅ | 25.4::193–200 | ∅ | ∅ | doi:10.1016/j.tips.2004.02.007 | ∅ | ∅ | ∅
2. Owen, R.P. et al | 2011 | "Pharmacogenomics in the Clinic" | Annual Review of Medicine | ∅ | 62::157–173 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
3. International Warfarin Pharmacogenetics Consortium | 2009 | "Estimation of the Warfarin Dose with Clinical and Pharmacogenomic Data" | New England Journal of Medicine | ∅ | 360.8::753–764 | ∅ | ∅ | doi:10.1056/nejmoa0809329 | ∅ | ∅ | ∅
4. Mallal, S. et al | 2008 | "HLA-B5701 Screening for Hypersensitivity to Abacavir" | New England Journal of Medicine* | ∅ | 358.6::568–579 | ∅ | ∅ | doi:10.1056/nejmoa0706135 | ∅ | ∅ | ∅
5. Relling, M.V.; Evans, W.E | 2015 | "Pharmacogenomics in the Clinic" | Nature | ∅ | 526::343–350 | ∅ | ∅ | doi:10.1038/nature15817 | ∅ | ∅ | ∅
6. Crews, K.R. et al | 2012 | "Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy" | Clinical Pharmacology & Therapeutics | ∅ | 91.2::321–326 | ∅ | ∅ | doi:10.1038/clpt.2011.287 | ∅ | ∅ | ∅
7. Gaedigk, A. et al | 2008 | "The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype" | Clinical Pharmacology & Therapeutics | ∅ | 83.2::234–242 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
8. Man, C.B.L. et al | 2007 | "Association between HLA-B1502 Allele and Antiepileptic Drug-Induced Cutaneous Reactions in Han Chinese" | Epilepsia* | ∅ | 48.5::1015–1018 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
9. Nebert, D.W. et al | 2013 | "Human Cytochromes P450 in Health and Disease" | Philosophical Transactions of the Royal Society B | ∅ | 368.1612::20120431 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
10. Johnson, J.A. et al | 2017 | "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing" | Clinical Pharmacology & Therapeutics | ∅ | 102.3::397–404 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
11. Kahn, J | 2004 | "How a Drug Becomes 'Ethnic': Law, Commerce, and the Production of Racial Categories in Medicine" | Yale Journal of Health Policy, Law, and Ethics | ∅ | 4.1::1–46 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
12. Fujikura, K. e0155552 | 2016 | "Global Carrier Rates of Rare Inherited Disorders Using Population Exome Sequences" | PLoS ONE | ∅ | 11.5:: | ∅ | ∅ | ∅ | ∅ | ∅ | ∅
13. Fujikura, K. et al | 2015 | "Genetic Variation in the Human Cytochrome P450 Supergene Family" | Pharmacogenomics and Genomics | ∅ | 25.12::584–594 | ∅ | ∅ | ∅ | ∅ | ∅ | ∅

CROSS-REFERENCE INDEX

Last Updated: March 9, 2026

<table border="1" cellpadding="12" cellspacing="0" style="border-collapse: collapse; border: 2px solid #888; margin-top: 2em; background: #fafafa;">

<tr><td>

⚠️ AI-Assisted Research Disclaimer

This document was generated and structured with the assistance of AI tools.

While every effort is made to ensure accuracy, AI-assisted content may

contain errors, misattributions, or unintended inaccuracies. **Always

verify claims, dates, and sources independently** before citing or relying

on any information presented here.

• Sources may contain errors. Bibliography entries and cross-references

are checked by automated systems, but mistakes can occur. If something

looks wrong, it may be.

• Speculative and unverified claims are clearly labeled. This project

uses a four-tier evidence system:

• Tier 1 — Verified: Peer-reviewed, established scientific consensus.
• Tier 2 — Credible: Academically supported, debated but grounded.
• Tier 3 — Speculative: Plausible but unverified by mainstream science.
• Tier 4 — Dubious: No credible support or contradicted by evidence.
• This project maps multiple perspectives — not a single truth. Mainstream,

alternative, and skeptical viewpoints are presented side by side for

critical comparison, not endorsement. Inclusion does not imply agreement.

• We are actively improving. Source verification, factuality scoring,

and bibliography enrichment are ongoing. Each revision adds stronger

citations, corrects identified errors, and expands coverage.

📖 For full details on our verification methodology, scoring systems, and

quality metrics, see: Fact-Checking & Verification Systems

Think Openly. Check the sources. Draw your own conclusions.

</td></tr>

</table>